Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
As a partner with IRIA, the company had a significant booth presence on-ground during the conference.
Novel tool bypasses plasmid-based expression to increase stability and significantly reduce development time for a variety of synthetic biotechnology products
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
The funding will accelerate the AI-driven healthcare company's market expansion into the global market and support new product development
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
New collaboration will help customers reach sustainability goals for high-performance Udel PSU polymers in demanding applications.
Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Subscribe To Our Newsletter & Stay Updated
